Orbillion, a developer of cultivated meat technology, has successfully scaled the production of its cultured beef muscle cells across North America, Europe and Asia.

According to the company, this accomplishment marks a critical step in making sustainable cultivated meat more accessible and overcoming long-standing challenges to its commercialisation.

Orbillion has also appointed Thomas Beck, a food industry veteran with over 30 years of experience at Nestlé and DSM Nutritional Products, to its board of directors. His expertise will support the business move to large-scale production and revenue growth.

Patricia Bubner, CEO of Orbillion, said: "This achievement is more than just another milestone-it's proof of our vision to make sustainable cultivated meat accessible worldwide. And Beck's strategic insight, combined with our innovative technology, positions us to overcome the final hurdles to commercial production and affordability."

Unlike other companies that use fibroblasts or genetic modification to adapt cells for production, Orbillion is said to be the 'only company' to scale real muscle and fat cells without genetic modification. Its "bioware" technology eliminates the need for time-consuming cell adaptation, enabling direct scaling from biopsy to production. This accelerates product development and market entry, reducing costs by up to SIM and cutting development time by nearly one and a half years.

Samet Yildirim, CTO of Orbillion, added: "This achievement is revolutionary-not just for Orbillion, but for the future of food. Direct scaling of beef muscle and fat cells – the very building blocks of meat – without GMO, serum or expensive growth factors, allows us to deliver the most tasty, sustainable and cost-effective cultivated meat the world has ever seen."

Overcoming cultivated meat challenges

Commercialising cultivated meat is hindered by processes designed for biopharmaceuticals, which are unsuitable for food production. Orbillion addresses this with three key innovations:

1. Direct scaling of real muscle and fat cells: Using its advanced computational “bioware,” Orbillion scales non-GMO cells more quickly and affordably.

2. Biopharma expertise: Leveraging the co-founders’ backgrounds in biopharmaceutical scale-up, Orbillion has reimagined bioprocesses specifically for food applications, optimising efficiency and reducing costs.

3. Controlled cellular environments: By precisely managing the microenvironment for cell growth, Orbillion reduces dependence on expensive growth factors, making its production model both scalable and cost-effective.

Beck added: "Orbillion's approach is game-changing...Their ability to scale real muscle and fat cells directly from biopsy is unparalleled and puts them ahead of the curve in delivering cultivated meat that is as close to traditional meat as possible – without compromising on sustainability or quality."

Top image: © Orbillion Bio

#Orbillion